Drug manufacturers may change the list prices of their drugs at any time after launch. Over the period from January 2022 to January 2023, more than 4,200 drug products had price increases, of which 46 percent were larger than the rate of inflation. The average drug price increase over the course of the period was 15.2 percent, which translates to $590 per drug product.
Out-of-Pocket Costs
Reports
Displaying 1 - 9 of 9. 10 per page. Page 1.
Advanced SearchFact Sheet, Report
Inflation Reduction Act Research Series: Trends in Utilization and Spending for Drugs Selected Under the Medicare Drug Price Negotiation Program
The Inflation Reduction Act (IRA) authorizes the Secretary of the Department of Health and Human Services (HHS) to negotiate prices directly with participating manufacturers for selected drugs that are high expenditure, single source drugs without generic or biosimilar competition.
Report
The Inflation Reduction Act of 2022: One Year Anniversary Highlights from ASPE Drug Pricing Reports
Introduction
Fact Sheet
State Fact Sheets: Impacts of the IRA and ACA on Lowering Health Care Costs
Expanding access to high-quality, affordable health care has been a priority of the Biden-Harris Administration.
Report to Congress
ASPE Report to Congress: Impact of Drug Shortages on Consumer Costs
Prescription drug shortages are an ongoing concern in the United States (U.S.). While prior analyses explore the frequency of drug shortages in the U.S., little is known about the extent to which U.S. shortages impact consumer costs and healthcare systems. Drug shortages impact consumer costs in various ways.
ASPE Issue Brief
Inflation Reduction Act Research Series: Medicare Part D Enrollee Savings from Elimination of Vaccine Cost-Sharing
Effective January 1, 2023, the Inflation Reduction Act (IRA) eliminated enrollee cost-sharing for recommended vaccines covered under Medicare Part D. In 2021, 3.4 million people received vaccines under Part D, and annual out-of-pocket costs were $234 million.
Report
Linking State Health Care Data to Inform Policymaking: Opportunities and Challenges
This posting includes a report prepared by the RAND Corporation, “State All Payer Claims Databases Understanding the Current Landscape and Challenges to Use,” which builds on a 2021 report “The History, Promise and Challenges of State All Payer Claims Databases.” The new report provides additional detail on the objectives of and use cases for APCDs, the current APCD landscape, and implementati
ASPE Issue Brief, Report
Estimated Savings of $5,000 to Each Medicare Beneficiary from Enactment Through 2022 Under the Affordable Care Act
This report provides estimates of Medicare Parts A, B, and D savings from the Affordable Care Act to seniors and people living with disabilities enrolled in traditional Medicare.
ASPE Issue Brief, Report
Medicare Beneficiary Savings and the Affordable Care Act
This Issue Brief provides estimates of Medicare Parts A, B, and D savings from the Affordable Care Act to seniors and people living with disabilities enrolled in traditional Medicare.